• 19 Oct 16

    Jubilant Biosys becomes the first company in India to install Agilent’s RapidFire/MS screening platform

Jubilant Biosys is proud to announce the addition of Agilent Technologies’ RapidFire/MS screening technology to its Integrated Drug Discovery Platform.

RapidFire is a robust solid phase extraction technology that enables fast label free detection of native compounds by mass spectrometry in a wide range of in vitro assays, DMPK/ADME studies, hit/lead applications for drug discovery across a broad spectrum of therapeutic areas and also for screening difficult targets that are not amenable to labeled assays. Jubilant Biosys’s Bengaluru facility will be the first in India to be equipped with Agilent’s state-of-the-art RapidFire High-Throughput Mass Spectrometry system technology.

“The installation of the Agilent RapidFire platform shows Jubilant’s continued commitment to make the necessary investments with an objective to remain on the cutting edge of drug discovery. This platform will enable us to increase our productivity and to enhance our capabilities to successfully meet the needs of our clients,” said Steven Hutchins, President, Jubilant Biosys (Drug Discovery Solutions).

“Agilent RapidFire solution enables our clients with increased accuracy, provides faster results, better economic value , enhanced analysis capabilities , improved efficiency while maintaining robustness and  we are pleased to see Jubilant Biosys being the first organization in India to take advantage of this cutting edge technology,” said Bharat Bhardwaj, Country Manager, Agilent Technologies.

About Jubilant Drug Discovery Solutions (JDDS)

JDDS comprises of Jubilant Biosys, Jubilant Chemsys and Jubilant Discovery Services and has presence in India in Bangalore, Noida and in Malvern (USA). These subsidiaries of Jubilant Life Sciences Ltd employ over 625 employees and have demonstrated expertise in multiple therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS & others. The business model includes proprietary in-house innovation, strategic investments as well as drug discovery services as the core components which are available for collaborative research, partnership and out-licensing. ; ;

For business enquiries: